Progress in vaccine development for infectious diseases-a Keystone Symposia report

Jennifer Cable; Barney S Graham; Richard A Koup; Robert A Seder; Katalin Karikó; Norbert Pardi; Dan H Barouch; Bhawna Sharma; Susanne Rauch; Raffael Nachbagauer; Mattias N E Forsell; Michael Schotsaert; Ali H Ellebedy; Karin Loré; Darrell J Irvine; Emily Pilkington; Siri Tahtinen; Elizabeth A Thompson; Yanis Feraoun; Neil P King; Kevin Saunders; Galit Alter; Syed M Moin; Kwinten Sliepen; Gunilla B Karlsson Hedestam; Hedda Wardemann; Bali Pulendran; Nicole A Doria-Rose; Wan-Ting He; Jennifer A Juno; Sila Ataca; Adam K Wheatley; Jason S McLellan; Laura M Walker; Julia Lederhofer; Lisa C Lindesmith; Holger Wille; Peter J Hotez; Linda-Gail Bekker

doi:10.1111/nyas.14975

Progress in vaccine development for infectious diseases-a Keystone Symposia report

Ann N Y Acad Sci. 2023 Jun;1524(1):65-86. doi: 10.1111/nyas.14975. Epub 2023 Apr 5.

Authors

Jennifer Cable¹, Barney S Graham², Richard A Koup³, Robert A Seder³, Katalin Karikó⁴, Norbert Pardi⁵, Dan H Barouch⁶, Bhawna Sharma⁷, Susanne Rauch⁸, Raffael Nachbagauer^{9

10}, Mattias N E Forsell¹¹, Michael Schotsaert^{9

12}, Ali H Ellebedy¹³, Karin Loré¹⁴, Darrell J Irvine^{15

16

17}, Emily Pilkington^{18

19}, Siri Tahtinen²⁰, Elizabeth A Thompson²¹, Yanis Feraoun²², Neil P King²³, Kevin Saunders²⁴, Galit Alter¹⁷, Syed M Moin³, Kwinten Sliepen²⁵, Gunilla B Karlsson Hedestam²⁶, Hedda Wardemann²⁷, Bali Pulendran²⁸, Nicole A Doria-Rose³, Wan-Ting He^{16

29}, Jennifer A Juno¹⁸, Sila Ataca³, Adam K Wheatley¹⁸, Jason S McLellan³⁰, Laura M Walker^{31

32}, Julia Lederhofer³, Lisa C Lindesmith³³, Holger Wille³⁴, Peter J Hotez^{35

36

37

38}, Linda-Gail Bekker³⁹

Affiliations

¹ PhD Science Writer, New York, New York, USA.
² Morehouse School of Medicine, Atlanta, Georgia, USA.
³ Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
⁴ BioNTech SE, Mainz, Germany.
⁵ Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
⁶ Harvard Medical School, Boston, Massachusetts, USA.
⁷ Gilead Sciences, Foster City, California, USA.
⁸ CureVac AG, Tübingen, Germany.
⁹ Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
¹⁰ Moderna, Cambridge, Massachusetts, USA.
¹¹ Department of Clinical Microbiology, Umeå University, Umeå, Sweden.
¹² Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai New York, New York, New York, USA.
¹³ Department of Pathology and Immunology; Center for Vaccines and Immunity to Microbial Pathogens; and The Andrew M. and Jane M. Bursky Center for Human Immunology & Immunotherapy Programs, Washington University School of Medicine, St. Louis, Missouri, USA.
¹⁴ Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
¹⁵ Koch Institute for Integrative Cancer Research; Department of Biological Engineering; and Department of Materials Science and Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
¹⁶ Consortium for HIV/AIDS Vaccine Development (CHAVD), Scripps Research Institute, La Jolla, California, USA.
¹⁷ Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts, USA.
¹⁸ Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria, Australia.
¹⁹ Department of Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Victoria, Australia.
²⁰ Genentech, South San Francisco, California, USA.
²¹ Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
²² Université Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-Immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Fontenay-aux-Roses, France.
²³ Department of Biochemistry and Institute for Protein Design, University of Washington, Seattle, Washington, USA.
²⁴ Human Vaccine Institute, Duke University, Durham, North Carolina, USA.
²⁵ Department of Medical Microbiology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
²⁶ Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
²⁷ Division of B Cell Immunology, German Cancer Research Center, Heidelberg, Germany.
²⁸ Institute for Immunity, Transplantation and Infection; Department of Pathology; and Department of Microbiology & Immunology, Stanford University School of Medicine, Stanford University, Stanford, California, USA.
²⁹ Department of Immunology and Microbiology and IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, USA.
³⁰ Department of Molecular Biosciences, University of Texas at Austin, Austin, Texas, USA.
³¹ Adimab, LLC, Lebanon, New Hampshire, USA.
³² New Hampshire and Adagio Therapeutics, Inc., Waltham, Massachusetts, USA.
³³ Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
³⁴ Centre for Prions and Protein Folding Diseases and Department of Biochemistry, University of Alberta, Edmonton, Alberta, Canada.
³⁵ Texas Children's Center for Vaccine Development, Departments of Pediatrics and Molecular Virology & Microbiology, National School of Tropical Medicine, Baylor College of Medicine, Houston, Texas, USA.
³⁶ James A Baker III Institute for Public Policy, Rice University, Houston, Texas, USA.
³⁷ Department of Biology, Baylor University, Waco, Texas, USA.
³⁸ Hagler Institute for Advanced Study and Scowcroft Institute of International Affairs, Bush School of Government and Public Service, Texas A&M University, College Station, Texas, USA.
³⁹ Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa.

PMID: 37020354
DOI: 10.1111/nyas.14975

Abstract

The COVID-19 pandemic has taught us many things, among the most important of which is that vaccines are one of the cornerstones of public health that help make modern longevity possible. While several different vaccines have been successful at stemming the morbidity and mortality associated with various infectious diseases, many pathogens/diseases remain recalcitrant to the development of effective vaccination. Recent advances in vaccine technology, immunology, structural biology, and other fields may yet yield insight that will address these diseases; they may also help improve societies' preparedness for future pandemics. On June 1-4, 2022, experts in vaccinology from academia, industry, and government convened for the Keystone symposium "Progress in Vaccine Development for Infectious Diseases" to discuss state-of-the-art technologies, recent advancements in understanding vaccine-mediated immunity, and new aspects of antigen design to aid vaccine effectiveness.

Keywords: antigen design; mRNA vaccines; structural vaccinology; vaccine delivery; vaccine hesitancy; vaccines.

Publication types

Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural

MeSH terms

COVID-19* / prevention & control
Communicable Diseases*
Humans
Pandemics / prevention & control
Vaccination
Vaccine Development
Vaccines* / therapeutic use

Substances

Vaccines